← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicstaleEnsem TherapeuticsPhase 2

alpelisib+fulvestrant (alpelisib+fulvestrant)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 26.6%임상시험 30상태 RECRUITING
CGTBiologicstaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 94%임상시험 30상태 RECRUITING
CGTBiologicstaleTakedaPhase 1

anti-CD19 CAR-NK (anti-CD19 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 0%임상시험 30상태 RECRUITING
CGTBiologicstaleHrain Biotechnology Co., Ltd.Preclinical

anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 32%임상시험 30상태 ACTIVE
AntibodystaleJunshi BiosciencesPhase 2

humanized anti-PD-1 monoclonal antibody toripalimab (humanized anti-PD-1 monoclonal antibody toripalimab)

Advanced Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 1

ketoconazole (ketoconazole)

Carcinomas; Disease, Hodgkin · Carcinomas

#Carcinomas#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 30상태 ACTIVE
CGTBiologicstaleBeijing Bio-Targeting Therapeut…Phase 2

oncolytic virus (oncolytic virus)

Glioblastoma (GBM) · Glioblastoma (GBM)

#GlioblastomaGBM#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 28%임상시험 30상태 RECRUITING
ADCBiologicstaleJiangsu HengRui Medicine Co., L…Phase 2

pyrotinib plus capecitabine (pyrotinib plus capecitabine)

Metastatic Breast Cancer in the Brain · Metastatic Breast Cancer in the Brain

#MetastaticBreastCancerintheBrain#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 30상태 RECRUITING
AntibodystaleJanssenApproved

teclistamab OR talquetamab OR elranatamab OR linvoseltamab (teclistamab OR talquetamab OR elranatamab OR linvoseltamab)

Waldenstrom Macroglobulinaemia; Multiple Myeloma · Waldenstrom Macroglobulinaemia

#WaldenstromMacroglobulinaemia#Antibody#Approved#항체#면역항체+3
효능 ORR 50%임상시험 30상태 RECRUITING
CGTBiologicstaleGlycostem Therapeutics BVPhase 1

umbilical cord blood NK cells (umbilical cord blood NK cells)

Neuroblastoma · Soft Tissue Sarcoma (STS)

#SoftTissueSarcomaSTS#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 30상태 RECRUITING
AntibodystaleEli LillyPhase 2

Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab))

Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 29상태 RECRUITING
AntibodyAbbViePhase 3

Budigalimab (Budigalimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 14.3%임상시험 29상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 1

GSK2857916 (GSK2857916)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 29상태 ACTIVE
ADCBiologicstaleAscentage Pharma Group Inc.Phase 2

Lisaftoclax (Lisaftoclax)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B Cell Lymphoma (DLBCL)

#DiffuseLargeBCellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 29상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

DS-1062a (DS-1062a)

Non-small Cell Lung Cancer · Metastatic Lung Cancer

#MetastaticLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 28상태 ACTIVE
CGTBiologicShanghai Cell Therapy Group Co.…Phase 1

Fast CAR T cells (Fast CAR T cells)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 28상태 RECRUITING
ADCBiologicstaleAbbViePhase 3

MIRV (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (MIRV))

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 28상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.5%임상시험 28상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 28상태 RECRUITING

36 / 209 페이지

← 이전다음 →